Payment overview · 2025
General Payments
$326.78
20 reported records · 7 companies
Healthcare provider profile · identity verified
Meihong Li, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EDISON, NJ · NPI 1407935356
Verified facts
What the public records show
CMS Open Payments records show Meihong Li, M.D. received $326.78 in general payments during 2025 across 20 reported records.
Lilly USA, LLC accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.84 | 27.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.89 | 23.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.57 | 16.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.12 | 14.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.97 | 9.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.94 | 4.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.45 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.78 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $88.84 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $71.83 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.46 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.57 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 15 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 98 |
| Metformin Hcl | Metformin Hcl | 224 | 65 |
| Alendronate Sodium | Alendronate Sodium | 125 | 47 |
| Simvastatin | Simvastatin | 118 | 36 |
| Losartan Potassium | Losartan Potassium | 111 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 18 |
| Valsartan | Valsartan | 52 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 15 |
| Azithromycin | Azithromycin | 46 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 46 | 14 |
| Lisinopril | Lisinopril | 45 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 12 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | 13 |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Repaglinide | Repaglinide | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 14 |
| Omeprazole | Omeprazole | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 11 |
| Carvedilol | Carvedilol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Glyburide | Glyburide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $326.78 · 20 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, Rybelsus, SHINGRIX, VOQUEZNA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error